{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:28:03Z","timestamp":1792700883054,"version":"4.5.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T00:00:00Z","timestamp":1739232000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T00:00:00Z","timestamp":1739232000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2019-01422"],"award-info":[{"award-number":["2019-01422"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol."],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The atypical antipsychotic clozapine targets multiple receptor systems beyond the dopaminergic pathway and influences prepulse inhibition (PPI), a critical translational measure of sensorimotor gating. Since PPI is modulated by atypical antipsychotics such as risperidone and clozapine, we hypothesized that p11\u2014an adaptor protein associated with anxiety- and depressive-like behaviors and G-protein-coupled receptor function\u2014might modulate these effects. In this study, we assessed the role of p11 in clozapine\u2019s PPI-enhancing effect by testing wild-type and global p11 knockout (KO) mice in response to haloperidol, risperidone, and clozapine. We also performed structural and functional brain imaging. Contrary to our expectation that anxiety-like p11-KO mice would exhibit an augmented startle response and heightened sensitivity to clozapine, PPI tests showed that p11-KO mice were unresponsive to the PPI-enhancing effects of risperidone and clozapine. Imaging revealed distinct regional brain volume differences and reduced hippocampal connectivity in p11-KO mice, with significantly blunted clozapine-induced connectivity changes in the CA1 region. Our findings highlight a novel role for p11 in modulating clozapine\u2019s effects on sensorimotor gating and hippocampal connectivity, offering new insight into its functional pathways.<\/jats:p>","DOI":"10.1038\/s41386-025-02060-z","type":"journal-article","created":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T17:40:36Z","timestamp":1739295636000},"page":"721-730","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A molecular mechanism mediating clozapine-enhanced sensorimotor gating"],"prefix":"10.1038","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6288-5439","authenticated-orcid":false,"given":"Ioannis","family":"Mantas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Flais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niclas","family":"Branzell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tudor M.","family":"Ionescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9461-8682","authenticated-orcid":false,"given":"Xiaoqun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5021-1234","authenticated-orcid":false,"given":"Diana","family":"Cash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastian","family":"Hengerer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6727-3802","authenticated-orcid":false,"given":"Per","family":"Svenningsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,11]]},"reference":[{"key":"2060_CR1","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1093\/schbul\/sby058","volume":"44","author":"FJ Charlson","year":"2018","unstructured":"Charlson FJ, Ferrari AJ, Santomauro DF, Diminic S, Stockings E, Scott JG, et al. Global epidemiology and burden of schizophrenia: findings from the global burden of disease study 2016. Schizophr Bull. 2018;44:1195\u2013203.","journal-title":"Schizophr Bull"},{"key":"2060_CR2","doi-asserted-by":"crossref","unstructured":"Buckley PF, Miller BJ, Lehrer DS, Castle DJ. Psychiatric comorbidities and schizophrenia. Schizophr Bull. 2009;35:383\u2013402.","DOI":"10.1093\/schbul\/sbn135"},{"key":"2060_CR3","doi-asserted-by":"publisher","first-page":"4234","DOI":"10.1038\/s41380-022-01687-4","volume":"27","author":"K Brosch","year":"2022","unstructured":"Brosch K, Stein F, Schmitt S, Pfarr JK, Ringwald KG, Thomas-Odenthal F, et al. Reduced hippocampal gray matter volume is a common feature of patients with major depression, bipolar disorder, and schizophrenia spectrum disorders. Mol Psychiatry. 2022;27:4234\u201343.","journal-title":"Mol Psychiatry"},{"key":"2060_CR4","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1001\/archpsyc.55.5.433","volume":"55","author":"MD Nelson","year":"1998","unstructured":"Nelson MD, Saykin AJ, Flashman LA, Riordan HJ. Hippocampal volume reduction in schizophrenia as assessed by magnetic resonance imaging: A meta-analytic study. Arch Gen Psychiatry. 1998;55:433\u201340.","journal-title":"Arch Gen Psychiatry"},{"key":"2060_CR5","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1176\/appi.ajp.2010.09081187","volume":"167","author":"CA Tamminga","year":"2010","unstructured":"Tamminga CA, Stan AD, Wagner AD. The hippocampal formation in schizophrenia. Am J Psychiatry. 2010;167:1178\u201393.","journal-title":"Am J Psychiatry"},{"key":"2060_CR6","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1176\/appi.ajp.161.11.1957","volume":"161","author":"P Videbech","year":"2004","unstructured":"Videbech P, Ravnkilde B. Hippocampal volume and depression: a meta-analysis of MRI studies. Am J Psychiatry. 2004;161:1957\u201366.","journal-title":"Am J Psychiatry"},{"key":"2060_CR7","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1126\/science.3854","volume":"192","author":"I Creese","year":"1976","unstructured":"Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science. 1976;192:481\u20133.","journal-title":"Science"},{"key":"2060_CR8","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1002\/wps.20567","volume":"17","author":"TS Stroup","year":"2018","unstructured":"Stroup TS, Gray N. Management of common adverse effects of antipsychotic medications. World Psychiatry. 2018;17:341\u201356.","journal-title":"World Psychiatry"},{"key":"2060_CR9","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","volume":"45","author":"J Kane","year":"1988","unstructured":"Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45:789\u201396.","journal-title":"Arch Gen Psychiatry"},{"key":"2060_CR10","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1146\/annurev-med-050911-161504","volume":"64","author":"HY Meltzer","year":"2013","unstructured":"Meltzer HY. Update on typical and atypical antipsychotic drugs. Annu Rev Med. 2013;64:393\u2013406.","journal-title":"Annu Rev Med"},{"key":"2060_CR11","first-page":"900","volume":"16","author":"YH Meltzer","year":"2017","unstructured":"Meltzer YH. New trends in the treatment of schizophrenia. CNS Neurol Disord Drug Targets. 2017;16:900\u20136.","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"2060_CR12","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nrd2806","volume":"8","author":"G Gr\u00fcnder","year":"2009","unstructured":"Gr\u00fcnder G, Hippius H, Carlsson A. The \u2018atypicality\u2019 of antipsychotics: a concept re-examined and re-defined. Nat Rev Drug Discov. 2009;8:197\u2013202. 2009 8:3","journal-title":"Nat Rev Drug Discov"},{"key":"2060_CR13","first-page":"4","volume":"61","author":"PE Keck","year":"2000","unstructured":"Keck PE, Strakowski SM, McElroy SL. The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia. J Clin Psychiatry. 2000;61:4\u20139.","journal-title":"J Clin Psychiatry"},{"key":"2060_CR14","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/S1566-2772(03)00021-5","volume":"3","author":"BL Roth","year":"2003","unstructured":"Roth BL, Sheffler D, Potkin SG. Atypical antipsychotic drug actions: unitary or multiple mechanisms for \u2018atypicality\u2019? Clin Neurosci Res. 2003;3:108\u201317.","journal-title":"Clin Neurosci Res"},{"key":"2060_CR15","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/BF02272148","volume":"28","author":"G Mengod","year":"1996","unstructured":"Mengod G, Vilar\u00f3 MT, Raurich A, L\u00f3pez-Gim\u00e9nez JF, Cortes R, Palacios JM. 5-HT receptors in mammalian brain: Receptor autoradiography and in situ hybridization studies of new ligands and newly identified receptors. Histochem J. 1996;28:747\u201358.","journal-title":"Histochem J"},{"key":"2060_CR16","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/S0301-0082(98)00092-6","volume":"58","author":"EA Van Der Zee","year":"1999","unstructured":"Van Der Zee EA, Luiten PGM. Muscarinic acetylcholine receptors in the hippocampus, neocortex and amygdala: a review of immunocytochemical localization in relation to learning and memory. Prog Neurobiol. 1999;58:409\u201371.","journal-title":"Prog Neurobiol"},{"key":"2060_CR17","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1111\/ejn.12570","volume":"40","author":"C Gelegen","year":"2014","unstructured":"Gelegen C, Gent TC, Ferretti V, Zhang Z, Yustos R, Lan F, et al. Staying awake \u2013 a genetic region that hinders \u03b12 adrenergic receptor agonist-induced sleep. Eur J Neurosci. 2014;40:2311\u20139.","journal-title":"Eur J Neurosci"},{"key":"2060_CR18","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S0891-0618(97)00042-2","volume":"13","author":"HEW Day","year":"1997","unstructured":"Day HEW, Campeau S, Watson SJ, Akil H. Distribution of \u03b11a-, \u03b11b- and \u03b11d-adrenergic receptor mRNA in the rat brain and spinal cord. J Chem Neuroanat. 1997;13:115\u201339.","journal-title":"J Chem Neuroanat"},{"key":"2060_CR19","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1001\/archpsyc.1994.03950020063007","volume":"51","author":"NR Swerdlow","year":"1994","unstructured":"Swerdlow NR. Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. Arch Gen Psychiatry. 1994;51:139.","journal-title":"Arch Gen Psychiatry"},{"key":"2060_CR20","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/00008877-200006000-00002","volume":"11","author":"NR Swerdlow","year":"2000","unstructured":"Swerdlow NR, Braff DL, Geyer MA. Animal models of deficient sensorimotor gating: what we know, what we think we know, and what we hope to know soon. Behavioural Pharmacol. 2000;11:185\u2013204.","journal-title":"Behavioural Pharmacol"},{"key":"2060_CR21","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S0920-9964(00)00139-0","volume":"49","author":"DL Braff","year":"2001","unstructured":"Braff DL, Geyer MA, Light GA, Sprock J, Perry W, Cadenhead KS, et al. Impact of prepulse characteristics on the detection of sensorimotor gating deficits in schizophrenia. Schizophr Res. 2001;49:171\u20138.","journal-title":"Schizophr Res"},{"key":"2060_CR22","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1111\/j.1469-8986.1978.tb01390.x","volume":"15","author":"D Braff","year":"1978","unstructured":"Braff D, Stone C, Callaway E, Geyer M, Glick I, Bali L. Prestimulus effects on human startle reflex in normals and schizophrenics. Psychophysiology. 1978;15:339\u201343.","journal-title":"Psychophysiology"},{"key":"2060_CR23","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1080\/15622975.2020.1770859","volume":"22","author":"ZI Storozheva","year":"2021","unstructured":"Storozheva ZI, Akhapkin RV, Bolotina OV, Korendrukhina A, Novototsky-Vlasov VY, Shcherbakova IV, et al. Sensorimotor and sensory gating in depression, anxiety, and their comorbidity. World J Biol Psychiatry. 2021;22:183\u201393.","journal-title":"World J Biol Psychiatry"},{"key":"2060_CR24","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1093\/oxfordjournals.schbul.a033326","volume":"24","author":"NR Swerdlow","year":"1998","unstructured":"Swerdlow NR, Geyer MA. Using an animal model of deficient sensorimotor gating to study the pathophysiology and new treatments of schizophrenia. Schizophr Bull. 1998;24:285\u2013301.","journal-title":"Schizophr Bull"},{"key":"2060_CR25","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/nrd1346","volume":"3","author":"BL Roth","year":"2004","unstructured":"Roth BL, Sheffler DJ, Kroeze WK. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov. 2004;3:353\u20139.","journal-title":"Nat Rev Drug Discov"},{"key":"2060_CR26","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.tips.2020.04.004","volume":"41","author":"JS Seo","year":"2020","unstructured":"Seo JS, Svenningsson P. Modulation of ion channels and receptors by p11 (S100A10). Trends Pharm Sci. 2020;41:487\u201397.","journal-title":"Trends Pharm Sci"},{"key":"2060_CR27","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrn3564","volume":"14","author":"P Svenningsson","year":"2013","unstructured":"Svenningsson P, Kim Y, Warner-Schmidt J, Oh YS, Greengard P. p11 and its role in depression and therapeutic responses to antidepressants. Nat Rev Neurosci. 2013;14:673\u201380.","journal-title":"Nat Rev Neurosci"},{"key":"2060_CR28","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.cell.2013.01.014","volume":"152","author":"YS Oh","year":"2013","unstructured":"Oh YS, Gao P, Lee KW, Ceglia I, Seo JS, Zhang X, et al. SMARCA3, a chromatin-remodeling factor, is required for p11-dependent antidepressant action. Cell. 2013;152:831\u201343.","journal-title":"Cell"},{"key":"2060_CR29","first-page":"77","volume":"311","author":"P Svenningsson","year":"2006","unstructured":"Svenningsson P, Chergui K, Rachleff I, Flajolet M, Zhang X, El Yacoubi M, et al. Alterations in 5-HT1B receptor function by p11 in depression-like states. Science (1979). 2006;311:77\u201380.","journal-title":"Science (1979)"},{"key":"2060_CR30","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.cell.2012.03.038","volume":"149","author":"EF Schmidt","year":"2012","unstructured":"Schmidt EF, Warner-Schmidt JL, Otopalik BG, Pickett SB, Greengard P, Heintz N. Identification of the cortical neurons that mediate antidepressant responses. Cell. 2012;149:1152\u201363.","journal-title":"Cell"},{"key":"2060_CR31","doi-asserted-by":"publisher","first-page":"3253","DOI":"10.1038\/s41380-020-00887-0","volume":"26","author":"VC Sousa","year":"2021","unstructured":"Sousa VC, Mantas I, Stroth N, Hager T, Pereira M, Jiang H, et al. P11 deficiency increases stress reactivity along with HPA axis and autonomic hyperresponsiveness. Mol Psychiatry. 2021;26:3253\u201365.","journal-title":"Mol Psychiatry"},{"key":"2060_CR32","doi-asserted-by":"publisher","first-page":"826","DOI":"10.4088\/JCP.v68n0602","volume":"68","author":"GI Papakostas","year":"2007","unstructured":"Papakostas GI, Shelton RC, Smith J, Fava M. Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder. J Clin Psychiatry. 2007;68:826\u201331.","journal-title":"J Clin Psychiatry"},{"key":"2060_CR33","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1073\/pnas.1524303113","volume":"113","author":"N Schintu","year":"2016","unstructured":"Schintu N, Zhang X, Alvarsson A, Marongiu R, Kaplitt MG, Greengard P, et al. P11 modulates L-DOPA therapeutic effects and dyskinesia via distinct cell types in experimental Parkinsonism. Proc Natl Acad Sci USA. 2016;113:1429\u201334.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2060_CR34","doi-asserted-by":"publisher","first-page":"243464","DOI":"10.3389\/fncel.2017.00019","volume":"11","author":"R Moreno-Paublete","year":"2017","unstructured":"Moreno-Paublete R, Canlon B, Cederroth CR. Differential neural responses underlying the inhibition of the startle response by pre-pulses or gaps in mice. Front Cell Neurosci. 2017;11:243464.","journal-title":"Front Cell Neurosci"},{"key":"2060_CR35","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.neuroimage.2011.09.015","volume":"62","author":"M Jenkinson","year":"2012","unstructured":"Jenkinson M, Beckmann CF, Behrens TEJ, Woolrich MW, Smith SM. FSL. Neuroimage. 2012;62:782\u201390.","journal-title":"Neuroimage"},{"key":"2060_CR36","doi-asserted-by":"crossref","unstructured":"Avants BB, Tustison NJ, Song G, Cook PA, Klein A, Gee JC. A reproducible evaluation of ANTs similarity metric performance in brain image registration. Neuroimage. 2011;54:2033\u20132044.","DOI":"10.1016\/j.neuroimage.2010.09.025"},{"key":"2060_CR37","doi-asserted-by":"crossref","unstructured":"Wood TC, Simmons C, Hurley SA, Vernon AC, Torres J, Dell\u2019Acqua F, et al. Whole-brain ex-vivo quantitative MRI of the cuprizone mouse model. PeerJ. 2016;4:e2632","DOI":"10.7717\/peerj.2632"},{"key":"2060_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2019.107829","volume":"162","author":"I Mantas","year":"2020","unstructured":"Mantas I, Yang Y, Mannoury-la-cour C, Millan MJ, Zhang X, Svenningsson P. Genetic deletion of GPR88 enhances the locomotor response to L-DOPA in experimental parkinsonism while counteracting the induction of dyskinesia. Neuropharmacology. 2020;162:107829.","journal-title":"Neuropharmacology"},{"key":"2060_CR39","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1109\/TUFFC.2009.1067","volume":"56","author":"G Montaldo","year":"2009","unstructured":"Montaldo G, Tanter M, Bercoff J, Benech N, Fink M. Coherent plane-wave compounding for very high frame rate ultrasonography and transient elastography. IEEE Trans Ultrason Ferroelectr Freq Control. 2009;56:489\u2013506.","journal-title":"IEEE Trans Ultrason Ferroelectr Freq Control"},{"key":"2060_CR40","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc: Ser B (Methodol). 1995;57:289\u2013300.","journal-title":"J R Stat Soc: Ser B (Methodol)"},{"key":"2060_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2023.120138","volume":"274","author":"PA Taylor","year":"2023","unstructured":"Taylor PA, Reynolds RC, Calhoun V, Gonzalez-Castillo J, Handwerker DA, Bandettini PA, et al. Highlight results, don\u2019t hide them: Enhance interpretation, reduce biases and improve reproducibility. Neuroimage. 2023;274:120138.","journal-title":"Neuroimage"},{"key":"2060_CR42","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/0091-3057(93)90193-W","volume":"44","author":"NR Swerdlow","year":"1993","unstructured":"Swerdlow NR, Geyer MA. Clozapine and haloperidol in an animal model of sensorimotor gating deficits in schizophrenia. Pharm Biochem Behav. 1993;44:741\u20134.","journal-title":"Pharm Biochem Behav"},{"key":"2060_CR43","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s002130050434","volume":"134","author":"J McCaughran Jr.","year":"1997","unstructured":"McCaughran J Jr., Mahjubi E, Decena E, Hitzemann R. Genetics, haloperidol-induced catalepsy and haloperidol-induced changes in acoustic startle and prepulse inhibition. Psychopharmacol (Berl). 1997;134:131\u20139.","journal-title":"Psychopharmacol (Berl)"},{"key":"2060_CR44","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/S0022-3565(25)23831-9","volume":"271","author":"VP Bakshi","year":"1994","unstructured":"Bakshi VP, Swerdlow NR, Geyer MA. Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response. J Pharm Exp Ther. 1994;271:787\u201394.","journal-title":"J Pharm Exp Ther"},{"key":"2060_CR45","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/0031-9384(89)90363-6","volume":"46","author":"LM Ford","year":"1989","unstructured":"Ford LM, Norman AB, Sanberg PR. The topography of MK-801-induced locomotor patterns in rats. Physiol Behav. 1989;46:755\u20138.","journal-title":"Physiol Behav"},{"key":"2060_CR46","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s00213-010-1938-0","volume":"212","author":"AM Bradford","year":"2010","unstructured":"Bradford AM, Savage KM, Jones DNC, Kalinichev M. Validation and pharmacological characterisation of MK-801-induced locomotor hyperactivity in BALB\/C mice as an assay for detection of novel antipsychotics. Psychopharmacol (Berl). 2010;212:155\u201370.","journal-title":"Psychopharmacol (Berl)"},{"key":"2060_CR47","doi-asserted-by":"publisher","first-page":"R9","DOI":"10.1016\/0014-2999(95)00333-G","volume":"280","author":"S Maurel-Remy","year":"1995","unstructured":"Maurel-Remy S, Bervoets K, Millan MJ. Blockade of phencyclidine-induced hyperlocomotion by clozapine and MDL 100,907 in rats reflects antagonism of 5-HT2A receptors. Eur J Pharm. 1995;280:R9\u2013R11.","journal-title":"Eur J Pharm"},{"key":"2060_CR48","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s002130051055","volume":"145","author":"MF O\u2019Neill","year":"1999","unstructured":"O\u2019Neill MF, Shaw G. Comparison of dopamine receptor antagonists on hyperlocomotion induced by cocaine, amphetamine, MK-801 and the dopamine D 1 agonist C-APB in mice. Psychopharmacol (Berl). 1999;145:237\u201350.","journal-title":"Psychopharmacol (Berl)"},{"key":"2060_CR49","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/0014-2999(76)90144-8","volume":"39","author":"DW Gallager","year":"1976","unstructured":"Gallager DW, Aghajanian GK. Effect of antipsychotic drugs on the firing of dorsal raphe cells. I. Role of adrenergic system. Eur J Pharm. 1976;39:341\u201355.","journal-title":"Eur J Pharm"},{"key":"2060_CR50","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s00213-003-1761-y","volume":"174","author":"PJ Harrison","year":"2004","unstructured":"Harrison PJ. The hippocampus in schizophrenia: a review of the neuropathological evidence and its pathophysiological implications. Psychopharmacol (Berl). 2004;174:151\u201362.","journal-title":"Psychopharmacol (Berl)"},{"key":"2060_CR51","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1177\/155005940803900209","volume":"39","author":"HC Cromwell","year":"2008","unstructured":"Cromwell HC, Mears RP, Wan L, Boutros NN. Sensory gating: a translational effort from basic to clinical science. Clin EEG Neurosci. 2008;39:69\u201372.","journal-title":"Clin EEG Neurosci"},{"key":"2060_CR52","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nrn3945","volume":"16","author":"P Tovote","year":"2015","unstructured":"Tovote P, Fadok JP, L\u00fcthi A. Neuronal circuits for fear and anxiety. Nat Rev Neurosci. 2015;16:317\u201331.","journal-title":"Nat Rev Neurosci"},{"key":"2060_CR53","doi-asserted-by":"publisher","first-page":"5001","DOI":"10.1093\/hmg\/ddt350","volume":"22","author":"AR Sanders","year":"2013","unstructured":"Sanders AR, G\u00f6ring HHH, Duan J, Drigalenko EI, Moy W, Freda J, et al. Transcriptome study of differential expression in schizophrenia. Hum Mol Genet. 2013;22:5001\u201314.","journal-title":"Hum Mol Genet"},{"key":"2060_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-019-0472-z","volume":"9","author":"EFW Bowen","year":"2019","unstructured":"Bowen EFW, Burgess JL, Granger R, Kleinman JE, Rhodes CH. DLPFC transcriptome defines two molecular subtypes of schizophrenia. Transl Psychiatry. 2019;9:147.","journal-title":"Transl Psychiatry"},{"key":"2060_CR55","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1007\/s12017-023-08743-4","volume":"25","author":"A Shamir","year":"2023","unstructured":"Shamir A, Yitzhaky A, Segev A, Haroutunian V, Katsel P, Hertzberg L. Up-regulation of S100 gene family in brain samples of a subgroup of individuals with schizophrenia: meta-analysis. Neuromolecular Med. 2023;25:388\u2013401.","journal-title":"Neuromolecular Med"},{"key":"2060_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jad.2016.02.010","volume":"196","author":"SW Park","year":"2016","unstructured":"Park SW, Nhu LH, Cho HY, Seo MK, Lee CH, Ly NN, et al. p11 mediates the BDNF-protective effects in dendritic outgrowth and spine formation in B27-deprived primary hippocampal cells. J Affect Disord. 2016;196:1\u201310.","journal-title":"J Affect Disord"},{"key":"2060_CR57","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1038\/sj.npp.1300277","volume":"28","author":"S Kusljic","year":"2003","unstructured":"Kusljic S, Copolov DL, van den Buuse M. Differential role of serotonergic projections arising from the dorsal and median raphe nuclei in locomotor hyperactivity and prepulse inhibition. Neuropsychopharmacology. 2003;28:2138\u201347.","journal-title":"Neuropsychopharmacology"},{"key":"2060_CR58","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/S0893-133X(00)00215-3","volume":"24","author":"P Fletcher","year":"2001","unstructured":"Fletcher P. Reduced brain serotonin activity disrupts prepulse inhibition of the acoustic startle reflex effects of 5,7-dihydroxytryptamine and p-chlorophenylalanine. Neuropsychopharmacology. 2001;24:399\u2013409.","journal-title":"Neuropsychopharmacology"},{"key":"2060_CR59","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/BF02245609","volume":"124","author":"JH Kehne","year":"1996","unstructured":"Kehne JH, Padich RA, McCloskey TC, Taylor VL, Schmidt CJ. 5-HT modulation of auditory and visual sensorimotor gating: I. Effects of 5-HT releasers on sound and light prepulse inhibition in Wistar rats. Psychopharmacol (Berl). 1996;124:95\u2013106.","journal-title":"Psychopharmacol (Berl)"},{"key":"2060_CR60","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/S0893-133X(99)00057-3","volume":"21","author":"J Sprouse","year":"1999","unstructured":"Sprouse J. Comparison of the novel antipsychotic ziprasidone with clozapine and olanzapine inhibition of dorsal raphe cell firing and the role of 5-HT1A receptor activation. Neuropsychopharmacology. 1999;21:622\u201331.","journal-title":"Neuropsychopharmacology"},{"key":"2060_CR61","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/npp.2010.195","volume":"36","author":"PN Yadav","year":"2011","unstructured":"Yadav PN, Abbas AI, Farrell MS, Setola V, Sciaky N, Huang X-P, et al. The presynaptic component of the serotonergic system is required for clozapine\u2019s efficacy. Neuropsychopharmacology. 2011;36:638\u201351.","journal-title":"Neuropsychopharmacology"},{"key":"2060_CR62","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1523\/JNEUROSCI.5343-08.2009","volume":"29","author":"JL Warner-Schmidt","year":"2009","unstructured":"Warner-Schmidt JL, Flajolet M, Maller A, Chen EY, Qi H, Svenningsson P, et al. Role of p11 in cellular and behavioral effects of 5-HT4 receptor stimulation. J Neurosci. 2009;29:1937\u201346.","journal-title":"J Neurosci"},{"key":"2060_CR63","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/(SICI)1096-9861(20000207)417:2<181::AID-CNE4>3.0.CO;2-A","volume":"417","author":"M Riad","year":"2000","unstructured":"Riad M, Garcia S, Watkins KC, Jodoin N, Doucet \u00c9, Langlois X, et al. Somatodendritic localization of 5-HT1A and preterminal axonal localization of 5-HT1B serotonin receptors in adult rat brain. J Comp Neurol. 2000;417:181\u201394.","journal-title":"J Comp Neurol"},{"key":"2060_CR64","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/0306-4522(94)90164-3","volume":"58","author":"U Boschert","year":"1994","unstructured":"Boschert U, A\u00eft Amara D, Segu L, Hen R. The mouse 5-hydroxytryptamine1B receptor is localized predominantly on axon terminals. Neuroscience. 1994;58:167\u201382.","journal-title":"Neuroscience"},{"key":"2060_CR65","doi-asserted-by":"publisher","unstructured":"Camargo A, Nilsson A, Shariatgorji R, Appleton E, Branzell N, Doyon D, et al. Enduring modulation of dorsal raphe nuclei regulates (R,S)-ketamine-mediated resilient stress-coping behavior. Mol Psychiatry. 2024. 2024. https:\/\/doi.org\/10.1038\/s41380-024-02853-6.","DOI":"10.1038\/s41380-024-02853-6"},{"key":"2060_CR66","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/sj.mp.4002062","volume":"12","author":"JA Gray","year":"2007","unstructured":"Gray JA, Roth BL. The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007;12:904\u201322.","journal-title":"Mol Psychiatry"},{"key":"2060_CR67","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/j.1749-6632.1998.tb10176.x","volume":"861","author":"SC Dulawa","year":"1998","unstructured":"Dulawa SC, Hen R, Scearce-Levie K, Geyer MA. 5-HT(1B) receptor modulation of prepulse inhibition: recent findings in wild-type and 5-HT(1B) knockout mice. Ann N. Y Acad Sci. 1998;861:79\u201384.","journal-title":"Ann N. Y Acad Sci"},{"key":"2060_CR68","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/S0893-133X(99)00164-5","volume":"22","author":"S Dulawa","year":"2000","unstructured":"Dulawa S. Knockout mice reveal opposite roles for serotonin 1A and 1B receptors in prepulse inhibition. Neuropsychopharmacology. 2000;22:650\u20139.","journal-title":"Neuropsychopharmacology"},{"key":"2060_CR69","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1177\/0963721410377601","volume":"19","author":"KH Karlsgodt","year":"2010","unstructured":"Karlsgodt KH, Sun D, Cannon TD. Structural and functional brain abnormalities in schizophrenia. Curr Dir Psychol Sci. 2010;19:226.","journal-title":"Curr Dir Psychol Sci"},{"key":"2060_CR70","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1038\/mp.2008.34","volume":"14","author":"D Sun","year":"2009","unstructured":"Sun D, Stuart GW, Jenkinson M, Wood SJ, McGorry PD, Velakoulis D, et al. Brain surface contraction mapped in first-episode schizophrenia: a longitudinal magnetic resonance imaging study. Mol Psychiatry. 2009;14:976\u201386.","journal-title":"Mol Psychiatry"},{"key":"2060_CR71","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41537-017-0013-9","volume":"3","author":"B Birur","year":"2017","unstructured":"Birur B, Kraguljac NV, Shelton RC, Lahti AC. Brain structure, function, and neurochemistry in schizophrenia and bipolar disorder\u2014a systematic review of the magnetic resonance neuroimaging literature. NPJ Schizophr. 2017;3:15.","journal-title":"NPJ Schizophr"},{"key":"2060_CR72","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.biopsych.2010.01.024","volume":"67","author":"M Egeland","year":"2010","unstructured":"Egeland M, Warner-Schmidt J, Greengard P, Svenningsson P. Neurogenic effects of fluoxetine are attenuated in p11 (S100A10) knockout mice. Biol Psychiatry. 2010;67:1048\u201356.","journal-title":"Biol Psychiatry"},{"key":"2060_CR73","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1002\/jnr.10281","volume":"69","author":"CG Wakade","year":"2002","unstructured":"Wakade CG, Mahadik SP, Waller JL, Chiu F. Atypical neuroleptics stimulate neurogenesis in adult rat brain. J Neurosci Res. 2002;69:72\u201379.","journal-title":"J Neurosci Res"},{"key":"2060_CR74","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.brainres.2005.09.043","volume":"1063","author":"C Luo","year":"2005","unstructured":"Luo C, Xu H, Li X-M. Quetiapine reverses the suppression of hippocampal neurogenesis caused by repeated restraint stress. Brain Res. 2005;1063:32\u201339.","journal-title":"Brain Res"},{"key":"2060_CR75","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/nrn2614","volume":"10","author":"NM Van Strien","year":"2009","unstructured":"Van Strien NM, Cappaert NLM, Witter MP. The anatomy of memory: an interactive overview of the parahippocampal\u2013hippocampal network. Nat Rev Neurosci. 2009;10:272\u201382.","journal-title":"Nat Rev Neurosci"},{"key":"2060_CR76","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1037\/0735-7044.122.4.885","volume":"122","author":"PA Csomor","year":"2008","unstructured":"Csomor PA, Yee BK, Vollenweider FX, Feldon J, Nicolet T, Quednow BB. On the influence of baseline startle reactivity on the indexation of prepulse inhibition. Behav Neurosci. 2008;122:885\u2013900.","journal-title":"Behav Neurosci"}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41386-025-02060-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-025-02060-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-025-02060-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T09:25:17Z","timestamp":1742203517000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41386-025-02060-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,11]]},"references-count":76,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["2060"],"URL":"https:\/\/doi.org\/10.1038\/s41386-025-02060-z","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,11]]},"assertion":[{"value":"14 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"IF, TMI and BH are employees at Boehringer Ingelheim. The other authors have nothing to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}